Welcome to our dedicated page for Lifeward news (Ticker: LFWD), a resource for investors and traders seeking the latest updates and insights on Lifeward stock.
Lifeward Ltd. (Nasdaq: LFWD) is a medical device company that focuses on technologies for physical rehabilitation and recovery, including the ReWalk Exoskeleton, ReWalk 7 Personal Exoskeleton, ReStore Exo-Suit, MyoCycle FES System, and AlterG Anti-Gravity System. This news page aggregates company press releases and third-party coverage so readers can follow how Lifeward’s business and strategy develop over time.
Recent news highlights Lifeward’s progress in reimbursement and market access for its ReWalk 7 Personal Exoskeleton. The company has reported prior authorization approvals and payments from Medicare Advantage plans, including UnitedHealthcare and a Humana Medicare Advantage Plan, following the establishment of a formal Medicare reimbursement pathway for personal exoskeletons by CMS. These updates provide insight into payer adoption trends and Lifeward’s efforts to support access for individuals with spinal cord injury.
Lifeward’s news flow also covers international expansion and regulatory milestones. The company announced CE mark approval for the ReWalk 7 Personal Exoskeleton, enabling commercial sales in Europe, and a distribution agreement with Verita Neuro to offer ReWalk in Mexico, Thailand, and the United Arab Emirates. These items help investors and clinicians understand how Lifeward is extending its commercial footprint beyond its core markets in the United States, Israel, and Germany.
Another important theme in Lifeward’s news is its strategic partnership with Oramed Pharmaceuticals. The parties have agreed to transfer Oramed’s Protein Oral Delivery (POD™) technology to Lifeward, with Oramed becoming a significant shareholder and managing the clinical program. Coverage of this transaction explains how Lifeward aims to operate as a biomedical portfolio company that combines revenue-generating MedTech products with longer-term biotech opportunities.
Visitors can use this page to review updates on financial results, capital raises, board and management changes, regulatory approvals, reimbursement developments, and strategic transactions involving LFWD.
Lifeward (Nasdaq: LFWD) entered a strategic partnership with Oramed (Nasdaq: ORMP) under which Lifeward will acquire Oramed's clinical-stage POD™ protein oral delivery platform and Oramed may acquire up to 49.99% of Lifeward. The transaction provides Lifeward access to up to $47 million via equity, convertible notes, milestone funding and warrants, and includes Oramed funding and managing planned POD™ clinical work.
The deal includes a 4% net-sales royalty on ReWalk for up to 10 years and preserves Lifeward’s focus on achieving cash‑flow profitability while adding biotech upside tied to oral insulin and other protein therapies.
Oramed Pharmaceuticals and Lifeward (NASDAQ: LFWD) signed binding agreements dated January 13, 2026 to transfer Oramed's POD™ oral drug delivery platform to Lifeward in exchange for Oramed receiving a 49.9% beneficial ownership interest upon satisfaction of closing conditions. Lifeward will issue two $10 million senior secured convertible notes (8% interest) with 100% warrant coverage; Oramed to invest $9M in each note. Oramed will fund and manage the upcoming clinical trial and receive 4% of net ReWalk sales for up to 10 years. Lifeward reported $26M revenue from ReWalk and AlterG in the last four quarters.
Lifeward (Nasdaq: LFWD) announced that its Board appointed Bob Marshall as Chairman, effective January 1, 2026. He will replace Joseph Turk, who will transition off the Board in connection with his new role at Fresenius Medical Care as Chief Executive Officer of Care Enablement.
Marshall has served on Lifeward's Board and as Chair of the Audit Committee since 2024, and is currently CFO and Treasurer of Lantheus Holdings (roles held since 2018). Management says Marshall’s financial leadership and public-company healthcare experience will support Lifeward’s strategic growth plans and patient-care objectives.
Lifeward (Nasdaq: LFWD) announced a distribution agreement with Singapore-based Verita Neuro to exclusively distribute the ReWalk Personal Exoskeleton initially in Mexico, Thailand, and the United Arab Emirates effective Dec. 17, 2025.
Verita will integrate ReWalk into intensive, daily in-patient neurorehabilitation programs and offer patient-specific setup and training, leveraging an international database of >25,000 spinal cord injury patients. Lifeward said the partnership supports a partner-led, capital-efficient commercial expansion and cites a $1.75 billion total addressable market for ReWalk.
Lifeward (Nasdaq: LFWD) announced that a Humana Medicare Advantage plan granted prior authorization for the ReWalk 7 personal exoskeleton on Dec 3, 2025, following a prior UnitedHealthcare approval in November.
Combined, Humana and UnitedHealthcare represent 47% of Medicare Advantage enrollees, increasing timely access for beneficiaries with spinal cord injury. The company said broader payer adoption and CMS's 2024 reimbursement pathway are improving reimbursement predictability and supporting stronger revenue and cash flow dynamics for U.S. scaling.
Lifeward (Nasdaq: LFWD) announced on Nov 17, 2025 that a UnitedHealthcare Medicare Advantage plan issued a prior authorization for a ReWalk 7 Personal Exoskeleton. The approval follows CMS's 2024 reimbursement pathway for personal exoskeletons and is presented as a step toward broader payer adoption in the U.S.
The company said the UnitedHealthcare prior authorization may improve predictability in reimbursement, accelerate prior authorizations, and support scalable growth and cash flow dynamics for beneficiaries using ReWalk 7.
Lifeward (Nasdaq: LFWD) reported Q3 2025 results on Nov 14, 2025: revenue $6.2M (Q3 2024: $6.1M), net loss $3.2M or $0.20 per share, and cash used in operations $3.8M.
Key operational progress included a record quarter of ReWalk placements for Medicare beneficiaries, a 16% year‑over‑year reduction in quarterly cash burn, a 27% decline in quarterly non‑GAAP operating loss, and CE mark approval for ReWalk 7 enabling sales in Europe (~40% of exoskeleton sales). Lifeward also secured a $3.0M loan from Oramed and reaffirmed 2025 guidance of $24–$26M revenue and $12–$14M non‑GAAP net loss.
Lifeward (NASDAQ: LFWD) will release its third quarter 2025 financial results before markets open on Friday, November 14, 2025. A conference call and live webcast with CEO Mark Grant and CFO Almog Adar is scheduled for 8:30 a.m. EST the same day to discuss results.
Analysts and investors can join via toll-free U.S. dial-in 1-833-316-0561, international dial-in 1-412-317-0690, or regional numbers including Germany and Israel; participants should reference the "Lifeward Earnings Call" access code. The live webcast is available on the company website GoLifeward.com in Investors or at https://edge.media-server.com/mmc/p/522gfyx4, with an archived replay to follow on the site.
Lifeward (NASDAQ:LFWD) has achieved a significant milestone by receiving its first payment from a commercial Medicare Advantage Plan for its ReWalk 7 Personal Exoskeleton. The company has reported accelerated claim processing times, with approvals now taking just 30-60 days, compared to previously longer timelines.
Following CMS's 2024 establishment of a Medicare reimbursement pathway for personal exoskeletons, Lifeward has successfully streamlined the claims process. The majority of Medicare claims are now being approved upon initial submission, eliminating the need for lengthy appeals processes.
Lifeward (Nasdaq: LFWD) has received CE mark approval for its ReWalk 7 Personal Exoskeleton, enabling commercial sales in Europe. The seventh-generation device features advanced capabilities including cloud connectivity, push-button control, customizable walking speeds, and improved stairs/curbs navigation.
Europe represents 40% of Lifeward's exoskeleton sales, with Germany being the second-largest market globally. The company has established reimbursement agreements with major German insurers, including BARMER, covering approximately 45% of people with statutory health insurance in Germany.
FAQ
What is the current stock price of Lifeward (LFWD)?
What is the market cap of Lifeward (LFWD)?
